kabutan

Veritas In Silico tumbles for first time in 3 sessions after ending joint drug discovery research with Takeda◇

Tue Apr 14, 2026 10:31 am JST Catalyst

Shares of Veritas In Silico <130A> plunged for the first time in three trading sessions. After the market close on the 13th, the company announced the termination of its joint drug discovery research on mRNA-targeted small molecule drugs with Takeda Pharmaceutical Company Limited <4502>, effective that same day. The news appeared to weigh heavily on the stock. Veritas In Silico stated that the collaboration was ending amicably after achieving certain milestones. Both companies will continue to explore potential future applications for the knowledge gained through the joint research.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles